Boan Biotech Presents Early Research Findings about Its Innovative Anti-CD25 Antibody (BA1106) at AACR Annual Meeting 2025

Yantai, April 29, 2025 – Boan Biotech presented the early research findings about its BA1106, a non-IL-2 blocking anti-CD25 antibody, at the 2025 Annual Meeting of the American Association for C...

FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 5 JUNE 2025 (APPLICABLE TO HOLDERS OF H SHARES)

NOTICE OF ANNUAL GENERAL MEETING

(1) 2024 REPORT OF THE BOARD OF DIRECTORS (2) 2024 REPORT OF THE BOARD OF SUPERVISORS (3) 2024 ANNUAL REPORT (4) PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR (5) PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR (6) RE-APPOINTMENT OF AUDITOR (7) REMUNERATION O

2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

ANNUAL REPORT 2024

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Phase 3 Trial Results of Boan Biotech’s Dulagutide Injection Published in Journal of Diabetes

April 21, 2025, Yantai -- The Phase 3 trial results of Boan Biotech’s BA5101 (Dulagutide Injection, formerly code-named LY05008) were recently published in Journal of Diabetes.BA5101 is a biosim...

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025

Boan Biotech Announces 2024 Financial Results

* Strong growth of RMB 190 million in net profit* Time to reap the benefits of R&DBoan Biotech (6955.HK) today announced its annual results for fiscal year 2024 and latest developments.In the repo...